Vitro Diagnostics Inc., which is doing business as Vitro Biopharma, is committed to harnessing the power of cells. The company owns US patents for the production of the fertility drug â€“ FSH, immortalization of cells, and a pending US patent regarding stem cell-based cancer treatments. Vitro also recently received a Notice of Allowance for its method of generation of adult stem cells.
Vitro announced the introduction of â€œTools for Stem Cell and Drug Developmentâ€ at the recently held Society of Toxicology meeting in Baltimore, MD. These products are designed to support stem cell and cancer research specifically targeting mesenchymal stem cells (MSCs) and a new type of stem cell called induced plurapotent stem cells (iPS). MSCs are adult stem cells that differentiate into several tissue-specific cells, such as collagen, bone and fat cells.
Expanded usage of adult stem cells, such as those provided by Vitro, provides two major benefits. First, use of Vitro’s adult stem cells eliminates ethical and religious issues associated with embryonic stem cells. Secondly, the use of Vitro’s adult stem cells will enable use of personalized cells that should eliminate immune rejection of transplanted cells.
Enhanced expression of certain genes in adult skin cells results in cells called iPS that resemble embryonic stem cells and may in the future eliminate the need for embryonic stem cells. However, current methods of iPS generation involve genetic engineering using foreign DNA sequences added to the cells being converted to iPS. This step adds considerable safety risks.
Vitro’s new tools will facilitate a breakthrough research â€“ generation of iPS without genetic engineering with foreign DNA. The company’s tools will do this by providing well-defined human cells and related products that may be converted to iPS without using foreign DNA material.
Vitro’s new products also offer important tools for stem cell therapy of cancer. MSCs migrate to cancer stem cells and this characteristic may be used to carry toxic agents to selectively eradicate cancer stem cells. This process should provide a novel cellular therapy to fight cancer with minimal side-effects.